Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dare Bioscience (DARE) Operating Income (2016 - 2025)

Dare Bioscience's Operating Income history spans 8 years, with the latest figure at -$1.5 million for Q4 2025.

  • For Q4 2025, Operating Income rose 72.69% year-over-year to -$1.5 million; the TTM value through Dec 2025 reached -$13.6 million, up 42.21%, while the annual FY2025 figure was -$13.6 million, 42.21% up from the prior year.
  • Operating Income reached -$1.5 million in Q4 2025 per DARE's latest filing, up from -$3.7 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $384322.0 in Q2 2022 to a low of -$16.2 million in Q4 2022.
  • Average Operating Income over 5 years is -$6.9 million, with a median of -$7.2 million recorded in 2022.
  • Peak YoY movement for Operating Income: soared 104.19% in 2022, then crashed 2439.02% in 2023.
  • A 5-year view of Operating Income shows it stood at -$9.5 million in 2021, then plummeted by 70.08% to -$16.2 million in 2022, then surged by 68.14% to -$5.2 million in 2023, then decreased by 4.19% to -$5.4 million in 2024, then soared by 72.69% to -$1.5 million in 2025.
  • Per Business Quant, the three most recent readings for DARE's Operating Income are -$1.5 million (Q4 2025), -$3.7 million (Q3 2025), and -$3.8 million (Q2 2025).